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KLK3a b s t r a c t
Prostatic hyperplasia is benign tumor occur in prostate. Benign prostatic hyperplasia is common disease
in old men. The incidence of disease arises with increase in age. The patient with benign prostatic hyper-
plasia are estimated 20% of men in 40s old, and 90% in of men in 80s old, and main causes of prostatic
hyperplasia are unknown but there is evidence referring to genetic and hormonal disorders that may
cause the disease. This study includes 60 patients with prostatic hyperplasia with an average age of
64 years old and 30 samples as a control with same age group. The study obtained that there was signif-
icant association (P  0.05) between PSA (KLK3) and prostatic hyperplasia. Result also mentions that
there was significant decrease in testosterone level and significant increase in dihydrotestosterone level.
The present study for KLK2 and KLK3 genes showed molecular variation in both genes, varied between
polymorphism and allele polymorphism. PCR amplification of specific primers of KLK2 gene showed poly-
morphisms ranged between 14%, 8%, 10%, and 6% in each KLK2a, KLK2b, KLK2c, and KLK2d primers
respectively, while the allele polymorphism in KLK2c amplification with primer reaches 18% of patient.
PCR amplification of specific primers of KLK3 gene showed polymorphisms ranged between 10%, 6%,
2%, and 4% in each KLK3a, KLK3b, KLK3c, and KLK3d primer respectively, and allele variation was not
detected in amplification product of KLK3.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Benign prostatic hyperplasia is a common disease in older
men,1 ranging from 20%, 40%, 70%, 80%, and 90% in men between
40, 50, 60, 70, and 80 years old respectively.2,3 Despite the avail-
ability of medical and surgical treatments for benign prostatic
hyperplasia, the understanding of the processes involved in patho-
logical benign growth in human prostate is not clear enough.1
At the level of the population, there are five categories that
increase the risk of benign prostatic hyperplasia regardless of
age, which are steroid hormones, sex hormones, genetics, lifestyle,
and infections.4
Since the inflationary growth of the transitional zone of the
prostate associated with prostate clinical hyperplasia may be the
result of the abnormal expression of genes that respond to main
androgens, this leads to an imbalance between cell division and
apoptosis.1Testosterone (TES) encourages the proliferation of prostate cells
and increases the size of prostate with age at natural men and
either man who have low levels of TES has prostate size smaller
than normal, but when it is overcome by the shortfall in TES level,
the size of the prostate increases, but only to normal within the
same age group.5 It has proven that the increase in testosterone
above normal limit could result in high risk of prostate cancer
rate.6
Kallikreins related peptides (KLKs) are a group of serine pro-
teases found in various tissues and biological fluids.7 KLKs divided
into two main categories are Plasma KLKs and Tissue KLKs.8 These
two groups vary widely in molecular weight, substrate, immuno-
logical characteristics, gene structure, and the type of Alcanin
release.7 All KLK genes encode single-chain preproenzymes with
lengths varying between 244 and 293 amino acid residues and
40% protein identity among each other.9
Gene expression of kallikreins related peptides has been
detected in many tissues and cell lines for many of the human
organs, so the kallikreins related peptides involved in a wide range
of physiological processes, including pressure regulating peel off
the skin, semen fluid liquefaction, tissue regeneration, regulating
inflammatory processes.10
Table 1
Primer and their size (refer this study).
Primer of KLK2 gens
Primer Sequence Size Annealing temperature
KLK2a F: TCATCCAGTCTCGGATTGTG 1235 60
R: GAGGAGGAGAGGCATGAGG
KLK2b F: TCACTCCCTTCCTGGTTCTG 997 59.5
R: GGGAGGCAGATGTCTGGTTA
KLK2c F: TGAGGGAAAGGGAGAGGATGA 725 61
R: CAAACCAGTCCCACAGGTGC
KLK2d F: ATCAGGTGGTCTATGGGGCTA 60
R: GCATTCACTATCCCCCGTCTT
KLK3a F: CACTGTTTCTTTTTCTCTTTTGGA 684 60.5
R: TAGGGATGACTCACCGAGCA
KLK3b F: TCTGATCACCGAACTGACCA 1345 59.5
R: CCCACTGGGAGAAAACAACT
KLK3c F: GGGTCTTCCTTTGGCATGGG 844 60
R: CCCCTTTGAGTTCAGTGTCCT
KLK3d F: GGGTGGGATCCACACTGAGA 923 59
R: CCTAGGCGGTTTCCTCATCTT
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in the very specific expression for each of KLK2 and KLK3 in the
prostate tissue, which qualifies them to be a biological marker
for prostate diseases. Prostatic specific antigen has particular
gained prominence in recent years as the most valuable tumor
marker and is currently used on a large scale for the diagnosis,
monitoring and examining cases of prostate cancer and enlarged
prostate. The KLK2 is expressed in prostate mainly in addition to
a number of other tissues in low rate such as breast, thyroid, and
salivary glands.11 This gene has several similarities with KLK3. This
gene encodes a protein with amino acid sequence similar to the
sequence of amino acids for PSA (KLK3) by 77%. As in the PSA
(KLK3), all of the mRNA of the KLK2 gene and protein KLK2 are
expressed in epithelial cacuminal human prostate cells and
secreted in the seminal fluid.12 Later, it was shown that KLK2
cleaves to pro-PSA to generate active PSA, and this evidence
strongly supports the physiological role for KLK2 in regulating
the activity of PSA (KLK3) These two particles perhaps work
together in normal, benign and cancerous prostate tissue.12
The regulation of kallikreins related peptides includes KLK2 and
KLK3 on the transcriptional and post-transcriptional level by ster-
oid hormones, and each of KLK2 and KLK3 is under the influence
of androgenic hormones, as a complex of androgen-receptor with
androgenic response element which is located at the beginning
of promoter to stimulate the expression of both gene elements.
The studies showed that the concentration of each of the KLK2
and KLK3 decreases after treatment with anti-androgen during
the process of sexual transformation.13
This study aimed to evaluate physiological parameter along
with molecular screening of KLK2 and KLK3 in patient with pro-
static hyperplasia in western parts of Iraq.2. Materials and methods
The study samples were collected from patients for the period
from 01/02/2016 until 05/15/2016, and the study included samples
in two groups.
Patient group consists of 60 men diagnosed with a benign pro-
static hyperplasia within the age group ranging between 45 and 80
years.
Control group composed of 30 samples, who were normal man
and who were not diagnosed to have any symptoms or signs of
prostatic hyperplasia.
The information was collected for each member of the sample
through a personal interview and recorded in a questionnaire pre-
pared in advance for this purpose.The concentration of each of
Testosterone, DHT, and tPSA was determined by following steps of
kits by ready-made analysis, according to the method of Enzyme-
linked immune sorbent assay (ELISA) using ELISA Reader device.
Genomic DNA extracted from the blood of 7 control samples
and 50 patient samples by Geneaid kit and the DNA were checked
by gel electrophoresis. Then the extracted DNA is detected and the
resulting PCR technique was done using Agarose gel and according
to Maniatis et al.14
Primers were designed using NCBI www.ncbi.nlm.nih.gov, to
detect possible mutations in patients compared with the natural
sequences on NCBI.
A pair of specialized primers was used to amplify exons of KLK2
and KLK3, 4 primers for each gene (Table 1), where the prefixes are
equipped lyophilized as 10 Bekomul/ll.3. Results and discussion
The questionnaire was conducted according to Index of Symp-
toms of the American Association of Urology (AUASI). A total of250 samples of people aged between 41 and 80 years, were asked
questions outlined in the questionnaire, 60 patient samples were
selected after they proved to be positive for benign prostatic
hyperplasia and 30 control samples did not have any symptoms
of hyperplasia.
Testosterone Hormone levels showed decrease (P  0.05) in
serum for people with benign prostatic hyperplasia (444.0) when
compared with the control sample (614.2).
This result is consistent with the findings of the Wayne et al.,15
who stated that the levels of testosterone hormone were low in
men over the age of 50 years and those with hypertrophic prostatic
hyperplasia when compared with healthy people of the same age
group.
The present study showed significant differences (P  0.05)
between benign prostatic hyperplasia and control group in relation
to DHT hormone level which was 70.21 and 57.17 in each group
respectively.
The current study, agreed with the findings of Habeeb16 and
Pentti and Jean.17, who found a significant increase in serum DHT
levels in benign prostatic hyperplasia patients.
This variation in levels may happen as a result of higher activity
enzyme 5-alpha reductase, leading to positive feedback and
increase the production of dihydrotestosterone levels, as a result
of the conversion of testosterone to dihydrotestosterone.16
It has been suggested that DHT may have a role in protecting
cells from apoptosis by restricting androgen receptors within cells
and thus increase cell division at the expense of apoptosis which
leads to hyperplasia.18
The present study recorded a significant increase (P  0.05) in
the level of serum prostatic specific antigen in patients with benign
prostatic hyperplasia (3.312) compared with control samples
(0.9033).
These results agreed with the findings of Nadler et al.19 and
Irani et al.20 as the cavity of the prostate gland contains high con-
centrations of PSA (KLK3) and there are a number of barriers
between the cavity and capillaries of these barriers include all of
the basement membrane, stroma prostate cells capillary endothe-
lial, and increasing levels of total PSA in the blood in patients with
benign prostatic hyperplasia as a result of damage to the barriers
between the epithelial layer and the bloodstream,21; usually, there
are a small amount of leaking of the prostatic specific antigen into
bloodstream, while in hyperplasia patients there are a large
amount of leaking.22 This is probably the reason leading to the
increase in PSA (KLK3) in men with benign prostatic hyperplasia.
Indeed, there is strong relation between values of PSA (KLK3)
and DHT, so high value of DHT may lead to expression of PSA
Fig. 1. Gel electrophoresis on Agarose gel in concentration 1.5% for a: KLK2a, b: KLK2b, c: KLK2c, and d: KLK2d.
Fig. 2. Gel electrophoresis on Agarose gel in concentration 1.5% for a: KLK3a, b: KLK3b, c: KLK3c, and d: KLK3d.
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tance in KLK3 gene regulation.13
The results of polymerase chain reaction of KLK2 gene showed
19 (38.00%) of the study sample suffering from various genetic dis-
orders represented the absence of the expected appearance in four
primers and it is distributed as follow, 14% for KLK2a, 8% for KLK2b,
10% for KLK2c, and 6% for KLK2d. The results of polymerase chain
reaction of the primer KLK2c also showed allele polymorphism in
9 samples, while not appears among the control group any absence
or variation in studied sites, as shown in Fig. 1.Results of the poly-
merase chain reaction of KLK3 gene showed 11 (22.00%), member
of the study sample suffering from various genetic disorders repre-
sented the absence expected from bands in different primers and
distributed as follows, 10% for KLK3a, 6% for KLK3b, 2% for KLK3c,
and (4%) for the first KLK3d, and the rest of the samples only gave
correct bands as expected as well as the control group did not
show any lack of bands, as described in Fig.2.
The phenomenon of nucleotide polymorphism may regulate
genes by stimulation or inhibition of them and may affect causing
a particular disease and its progress, and genetic strategy pro-
posed, such as the phenomenon of single nucleotide polymorphism
as one of the causes of benign prostatic hyperplasia, where they
were to determine the number of point mutations in several genes
may have a positive effect on prostate growth and inflation.23
The genetic targets such as SNPs may evaluate as genetic signs
promising to better understand genetic bases of various complex
diseases, including benign tumor or cancer.24
Single nucleotide polymorphism represents approximately 90%
of the variations. This means that the SNPs are most common vari-
ations in human genome.25
But these SNPs that occur in the prostate specific genes and
their role in pathogenicity and disease progression for prostate
hyperplasia are not entirely clear.26 As functional SNPs are based
on the location of polymorphisms, its regulation with protein pro-
duction and maturation depends on the type of mutation which
may lead to change in cellular processes and function of cells.25
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